Life Sciences Lending News Today : Breaking News, Live Updates & Top Stories | Vimarsana

- Amendment of commercial and regulatory milestones for $50 million of additional non-dilutive capital to support launch of Motiva Implants® in U.S. ...

Oaktree Capital Management closed its Life Sciences Lending Fund and its related vehicles (“the Fund”), with total capital commitments in excess of $2.3 billion. The Fund, which is Oaktree’s first dedicated life sciences fund, was oversubscribed and builds on our track record of successfully investing in this specialized field for over a decade...

Seres Therapeutics, a leading microbiome therapeutics company, entered into a new $250 million senior secured debt facility ("Term Loan Facility") provided by funds managed by Oaktree Capital Management. The Company drew the first tranche of $110 million at closing, with three additional tranches available. These additional tranches include $90...

Harrow, a leading U.S. eyecare pharmaceutical company, entered into a $100 million secured credit financing agreement with funds managed by Oaktree Capital Management. The interest-only secured credit facility carries an interest rate equal to the three-month secured overnight financing rate (SOFR) plus 6.50%, includes flexible terms and covenants...

SCPH's lead drug candidate FUROSCIX was approved on October 10th by the FDA. To help distribute the drug, SCPH secured a $100 million loan. Read more here.